Wearable biometric diagnostic patch company VitalConnect said yesterday it raised $38 million in its fourth and final Series C closing, with funds slated to support the launch of its VitalConnect platform and VitalPatch wearable.
The round was led by MVM and joined by Baxter‘s (NYSE:BAX) venture arm, Baxter Ventures, the San Jose, Calif.-based company said.
VitalConnect produces the VitalPatch wearable biosensor, as well as its VitalConnect Platform to enable monitoring of the patch’s sensor data.
The company’s devices can return multiple measurements in a single biosensor patch, including single-lead ECG data, heart rate, RR interval, heart rate variability, respiratory rate, skin temperature, body posture, fall detection and activity including steps, according to the company’s website.
“We envision a hospital of the future where inpatient and outpatient care needs integrate more seamlessly to enable a patient-centric model of care that is truly preventative and real-time. Our close of $38 million in total financing this year will help drive our continued product development and rollout,” founder & CEO Nersi Nazari said in a press release.
VitalConnect launched in 2011 and raised Series A funding of $12 million that year, with a $22 million Series B that closed in 2016, the company said.
The company announced an earlier closing of its Series C round, having raised $33 million, back in May.
